U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07818018) titled 'A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma' on Sept. 08.
Brief Summary: The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatment approach for participants with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma
Study Start Date: Sept. 04
Study Type: INTERVENTIONAL
Condition:
Esophageal Cancer
Advanced Esophageal Cancer
Gastric Cancer
Advanced Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Advanced Gastroesophageal Junction Adenocarcinom...